|
|
Latest Thyroid Cancer - General News
Vandetanib Delays Progression of Advanced Medullary Thyroid Cancer (7/16/2010)
Results of a Phase III clinical trial indicate that the investigational drug vandetanib delays the progression of locally advanced or metastatic medullary thyroid cancer. These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Zactima™ Active Against Hereditary Medullary Thyroid Cancer (1/14/2010)
Results of a Phase II clinical trial indicate that Zactima™ (vandetanib) has significant activity for the treatment of patients with advanced, hereditary medullary thyroid cancer. These results were published in the Journal of Clinical Oncology.
Childhood Cancer Survivors at Risk for Thyroid Cancer (11/2/2009)
Survivors of childhood cancer are 18 times more likely to develop thyroid cancer than the general population, according to the results of a study published in the International Journal of Cancer.
Targeted Radiotherapy Shows Promise for Iodine-refractory Thyroid Cancer (5/18/2009)
According to results from a Phase II clinical trial, use of targeted radiation therapy with [90Yttrium-DOTA]-TOC may improve outcomes among patients with iodine-refractory, metastatic thyroid cancer. These results were published in Cancer.
Two Genetic Variations Linked to Thyroid Cancer (3/26/2009)
Scientists have discovered two genetic variations that result in a substantially increased risk of thyroid cancer, according to the results of a study published in Nature Genetics.
|
